Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.35 |
| ▸ | PDK2 | Q15119 | 4/20 | 0.34 |
| ▸ | CCR1 | P32246 | 2/20 | 0.33 |
| ▸ | CCR5 | P51681 | 2/20 | 0.33 |
| ▸ | CCR8 | P51685 | 2/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.30 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.30 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.30 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL80309 | 0.93 | CCR1 (0.44) | KDM4EPDK2CCR1CCR5CCR8 | |
| SCHEMBL80785 | 0.92 | PDK2 (0.34) | KDM4EPDK2KMT2APDGFRBPDGFRA | |
| SCHEMBL81183 | 0.89 | PDK2 (0.38) | PDK2KMT2A | |
| SCHEMBL82016 | 0.87 | PDGFRB (0.41) | KMT2APDGFRBPDGFRA | |
| SCHEMBL81955 | 0.86 | MAOB (0.38) | KDM4EKMT2AADORA2AADORA1PDGFRB | |
| SCHEMBL82033 | 0.86 | PDGFRB (0.36) | PDK2KMT2APDGFRBPDGFRA | |
| SCHEMBL80800 | 0.85 | KMT2A (0.36) | KDM4EPDK2KMT2A | |
| SCHEMBL80251 | 0.85 | MAOB (0.38) | KDM4EKMT2AADORA2AADORA1PDGFRB | |
| SCHEMBL81168 | 0.84 | PDK2 (0.38) | PDK2KMT2A | |
| SCHEMBL82037 | 0.84 | KMT2A (0.35) | KDM4EPDK2KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8129899-B1 | Azafluorene derivative and organic light-emitting device using the derivative | CANON KABUSHIKI KAISHA (JP) | 2012-03-06 | — | — | US | disclosed |
| US-8129899-B1 | Azafluorene derivative and organic light-emitting device using the derivative | CANON KABUSHIKI KAISHA (JP) | 2012-03-06 | — | — | US | disclosed |
| US-20120049176-A1 | AZAFLUORENE DERIVATIVE AND ORGANIC LIGHT-EMITTING DEVICE USING THE DERIVATIVE | CANON KABUSHIKI KAISHA (JP) | 2012-03-01 | — | — | US | disclosed |
| US-20120049176-A1 | AZAFLUORENE DERIVATIVE AND ORGANIC LIGHT-EMITTING DEVICE USING THE DERIVATIVE | CANON KABUSHIKI KAISHA (JP) | 2012-03-01 | — | — | US | disclosed |
| US-8110685-B2 | Efficient, durable electron transport layers; low driving voltage; simple, low cost production | CANON KABUSHIKI KAISHA (JP) | 2012-02-07 | — | — | US | disclosed |
| US-8110685-B2 | Efficient, durable electron transport layers; low driving voltage; simple, low cost production | CANON KABUSHIKI KAISHA (JP) | 2012-02-07 | — | — | US | disclosed |
| US-20080154040-A1 | AZAFLUORENE DERIVATIVE AND ORGANIC LIGHT-EMITTING DEVICE USING THE DERIVATIVE | CANON KABUSHIKI KAISHA (JP) | 2008-06-26 | — | — | US | disclosed |
| US-20080154040-A1 | AZAFLUORENE DERIVATIVE AND ORGANIC LIGHT-EMITTING DEVICE USING THE DERIVATIVE | CANON KABUSHIKI KAISHA (JP) | 2008-06-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080154040-A1 | AZAFLUORENE DERIVATIVE AND ORGANIC LIGHT-EMITTING DEVICE USING THE DERIVATIVE | AZI2, CYP1A2, CYP2C19 | KDM4E 852/4885PDK2 663/4885CCR1 4781/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.